News

ALS researchers worldwide continue to build upon existing work and make new discoveries in the hopes of a world free of ALS. In the April 2025 Research Update, explore new insights into clinical trial data, new treatment targets, predicting disease…

In a significant moment for the ALS community, Qalsody (tofersen) has been approved in Canada for the treatment of ALS in adults who have a pathogenic variant (also known as a mutation) in the superoxide dismutase 1 (SOD1) gene. This…

This blog series is a place for the ALS community to learn about and stay updated on ALS Canada's advocacy efforts as well as relevant developments within the government. Please note that because ALS Canada…

From the Research Desk highlights recent activities and accomplishments from the ALS Canada Research Team. From global conferences to impactful partnerships, our Research Team had a strong start to 2025.  By actively engaging with the global ALS community, supporting ALS…

Université de Montréal researcher awarded $250,000 over three years for a research study exploring a therapeutic approach with the potential to unlock new treatments Toronto, ON — The ALS Society of Canada (ALS Canada) and Brain Canada continue their…

Medals were presented to Canadians to recognize their contributions to advocacy, research, and support towards a world free of ALS Toronto, ON - The ALS Society of Canada (ALS Canada) was honoured to be selected to recognize 39 Canadians…

The ALS Society of Canada (ALS Canada) is proud to launch the Children and Youth Resource Hub to provide children, youth, and families with important educational materials that support the understanding of amyotrophic lateral sclerosis (ALS) – a disease that…

ALS Canada has submitted the patient input submission for Canada’s Drug Agency (CDA)’s review of QALSODY (tofersen), a therapy recently approved by Health Canada. This submission is a crucial step in ensuring that voices of the ALS community are reflected…